Induction of apoptosis of human colon cancer cells by siRNA recombinant expression vector targeting survivin gene

Abstract

This study constructed siRNA recombinant expression vector targeting survivin gene and observe the apoptosis induction effect of it in human colon cancer cells. siRNA recombinant expression vector targeting survivin gene was constructed and transfected into human colon cancer cells. The effect of siRNA recombinant expression vector was detected by RT-PCR, Western blot, MTT reduction assay and flow cytometry. It was confirmed by restriction endonuclease and sequence analysis that siRNA recombinant expression vector targeting survivin gene was constructed successfully. Inhibition rate of survivin siRNA at mRNA and protein levels was 36.33% and 44.65% respectively. Growth of cancer cells was inhibited and the apoptosis rate was (17.24±2.13)%. The siRNA recombinant expression vector targeting survivin gene has been constructed successfully. It not only can inhibit the expression of survivin gene, but also can induce apoptosis in human colon cancer cells remarkably.

Keywords

Survivin / RNA interference / gene therapy

References

[1] ElbashirS. M., HarborthJ., LendeckelW., et al. . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411(6836): 494-498

[2] MittalV.. Improving the efficiency of RNA interference in mammals. Nat Rev Genet, 2004, 5(5): 355-365

[3] Moffat J, Sabatini DM. Building mammalian signalling pathways with RNAi screens. Nat Rev Mol Cell Biol, 2006,(3):177–187

[4] KimD.H., RossiJ.J.. Strategies for silencing human disease using RNA interference. Nat Rev Genet, 2007, 8(3): 173-184

[5] FuesselS., HerrmannJ., NingS., et al. . Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett, 2006, 232(2): 243-254

[6] KamiK., DoiR., KoizumiM., et al. . Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery, 2005, 138(2): 299-305

[7] CheungH.H., LaCasseE.C., KornelukR.G.. X-linked inhibitor of apoptosis antagonism: strategies in cancer treatment. Clin Cancer Res, 2006, 12(11): 3238-3242

[8] WrightC.W., DuckettC. S.. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest, 2005, 115(10): 2673-2678

[9] JohnsonM.E., HowerthE.W.. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol, 2004, 41(6): 599-607

[10] ChunJ.Y., HuY., PinderE.. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther, 2007, 6(9): 2572-2580

[11] AltieriD.C.. Validating survivin as a cancer therapeutic target. Nat Rev Cancer, 2002, 3(1): 46-54

[12] LiF., BrattainM.G.. Role of the Survivin gene in pathophysiology. Am J Pathol, 2006, 169(1): 1-11

[13] SahN.K., KhanZ., KhanG.J., et al. . Structural, functional and therapeutic biology of survivin. Cancer Lett, 2006, 244(2): 164-171

[14] VerdeciaM.A., HuangH., DutilE.. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol, 2000, 7(8): 620-623

[15] DuffyM.J., O’DonovanN., BrennanD.J., et al. . Survivin: a promising tumor biomarker. Cancer Lett, 2007, 249(1): 49-60

[16] NotonE.A., ColnaghiR., TateS.. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem, 2006, 281(2): 1286-1295

[17] CaldasH., HonseyL.E., AlturaR.A.. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer, 2005, 4(1): 11

[18] MahotkaC., KriegT., KriegA.. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer, 2002, 100(1): 30-36

[19] LiF.. Role of survivin and its splice variants in tumorigenesis. Br J Cancer, 2005, 92(2): 212-216

[20] PennatiM., FoliniM., ZaffaroniN.. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis, 2007, 28(6): 1133-1139

[21] RosaJ., CanovasP., IslamA., et al. . Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell, 2006, 17(3): 1483-1493

[22] AltieriD.C.. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol, 2006, 18(6): 609-615

[23] WheatleyS.P., HenzingA.J., DodsonH., et al. . Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo. J Biol Chem, 2004, 279(7): 5655-5660

[24] VongQ.P., CaoK., LiH.Y.. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science, 2005, 310(5753): 1443-1444

[25] HondaR., KörnerR., NiggE.A.. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell, 2003, 14(8): 3325-3341

[26] DohiT., BeltramiE., WallN. R., et al. . Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest, 2004, 14(8): 1117-1127

[27] AltieriD.C.. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem, 2004, 92(4): 656-663

[28] ZaffaroniN., PennatiM., DaidoneM.G.. Survivin as a target for new anticancer interventions. J Cell Mol Med, 2005, 9(2): 360-372

[29] VaderG., KauwJ.J., MedemaR.H., et al. . Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep, 2006, 7(1): 85-92

[30] MesriM., Morales-RuizM., AckermannE.J., et al. . Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol, 2001, 158(5): 1757-1765

[31] TranJ., MasterZ., YuJ.L., et al. . A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA, 2002, 99(7): 4349-4354

[32] Blanc-BrudeO.P., YuJ., SimosaH., et al. . Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med, 2002, 8(9): 987-994

[33] KawasakiH., ToyodaM., ShinoharaH., et al. . Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer, 2001, 91(11): 2026-2032

[34] TakaiN., MiyazakiT., NishidaM., et al. . Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett, 2002, 184(1): 105-116

[35] KaurP., KallakuryB.S., SheehanC.E., et al. . Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med, 2004, 128(1): 39-43

[36] OlieR.A., Simões-WüstA.P., BaumannB., et al. . A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res, 2000, 60(11): 2805-2809

[37] HayashiN., AsanoK., SuzukiH., et al. . Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate, 2005, 65(1): 10-19

[38] FalleniM., PellegriniC., MarchettiA., et al. . Survivin gene expression in early-stage non-small cell lung cancer. J Pathol, 2003, 200(5): 620-626

[39] TanakaK., IwamotoS., GonG., et al. . Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res, 2000, 6(1): 127-134

[40] KountourasJ., ZavosC., ChatzopoulosD.. Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. J Surg Oncol, 2005, 90(4): 249-259

[41] GrabowskiP., KühnelT., Mühr-WilkenshoffF., et al. . Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer, 2003, 88(1): 115-119

[42] LinL.J., ZhengC.Q., JinY., et al. . Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol, 2003, 9(5): 974-977

[43] HannonG.J., RossiJ.J.. Unlocking the potential of the human genome with RNA interference. Nature, 2004, 431(7006): 371-378

This project was supported by grants from National High Technology Research and Development Program of China (No. 2001AA218051) and Educational Commission of Hubei Province of China (No. 2005A304B09).